Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study)

The 4-year clinical outcomes for perioperative toripalimab plus chemotherapy in resectable stage III NSCLC showed a sustained improvement in long-term EFS and OS. However, the effectiveness of adjuvant immunotherapy are still unclear, as definitive conclusions are limited by cohort size.

Authors

Wenyu Zhai
Ze-Rui Zhao (ORCID: https://orcid.org/0000-0001-9911-9965)
Hao Long
Yaobin Lin (ORCID: https://orcid.org/0000-0002-6716-0530)
Yuheng Zhou (ORCID: https://orcid.org/0000-0003-3118-604X)
Weizhen Sun
Shoucheng Feng

Institutions

Sun Yat-sen University (CN)
Sun Yat-sen University Cancer Center (CN)

Publication Details

Journal: Journal of Thoracic Disease
Published: 2025-05-01
DOI: https://doi.org/10.21037/jtd-2024-2266
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study)

Wenyu Zhai, Ze-Rui Zhao, Hao Long, Yaobin Lin et al.

May 1, 2025

Journal of Thoracic Disease

Lung Cancer Treatments and Mutations

article

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study)

Wenyu Zhai, Ze-Rui Zhao, Hao Long, Yaobin Lin, Yuheng Zhou, Weizhen Sun, Shoucheng Feng

May 1, 2025article en

Abstract

The 4-year clinical outcomes for perioperative toripalimab plus chemotherapy in resectable stage III NSCLC showed a sustained improvement in long-term EFS and OS. However, the effectiveness of adjuvant immunotherapy are still unclear, as definitive conclusions are limited by cohort size.

Journal of Thoracic DiseaseVol. 17(5)

Sun Yat-sen University (CN), Sun Yat-sen University Cancer Center (CN)

Good health and well-being

Openalex Percentile: Top 80%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study) — Wenyu Zhai, Ze-Rui Zhao, et al. · Journal of Thoracic Disease (2025) | TGRS Research Map | TGRS